دورية أكاديمية
أعرض في EDS

Immunogenicity of PvCyRPA, PvCelTOS and Pvs25 chimeric recombinant protein of Plasmodium vivax in murine model.

التفاصيل البيبلوغرافية
العنوان: Immunogenicity of PvCyRPA, PvCelTOS and Pvs25 chimeric recombinant protein of Plasmodium vivax in murine model.
المؤلفون: Matos ADS; Immunoparasitology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil., Soares IF; Immunoparasitology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil., Rodrigues-da-Silva RN; Hantaviruses and Rickettsioses Laboratory, IOC, Fiocruz, Rio de Janeiro, Brazil., Rodolphi CM; Parasitology Research Center, Federal University of Juiz de Fora (UFJF), Juiz de Fora, Brazil., Albrecht L; Apicomplexa Research Laboratory, Carlos Chagas Institute, Curitiba, Brazil., Donassolo RA; Apicomplexa Research Laboratory, Carlos Chagas Institute, Curitiba, Brazil., Lopez-Camacho C; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom., Ano Bom APD; Immunological Technology Laboratory, Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz), Rio de Janeiro, Brazil., Neves PCDC; Immunological Technology Laboratory, Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz), Rio de Janeiro, Brazil., Conte FP; Eukaryotic Pilot Laboratory, Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz), Rio de Janeiro, Brazil., Pratt-Riccio LR; Malaria Research Laboratory, IOC, Fiocruz, Rio de Janeiro, Brazil., Daniel-Ribeiro CT; Malaria Research Laboratory, IOC, Fiocruz, Rio de Janeiro, Brazil., Totino PRR; Malaria Research Laboratory, IOC, Fiocruz, Rio de Janeiro, Brazil., Lima-Junior JDC; Immunoparasitology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil.
المصدر: Frontiers in immunology [Front Immunol] 2024 Jun 19; Vol. 15, pp. 1392043. Date of Electronic Publication: 2024 Jun 19 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: Plasmodium vivax*/immunology , Plasmodium vivax*/genetics , Antigens, Protozoan*/immunology , Antigens, Protozoan*/genetics , Malaria, Vivax*/immunology , Malaria, Vivax*/prevention & control , Antibodies, Protozoan*/immunology , Mice, Inbred BALB C* , Malaria Vaccines*/immunology , Protozoan Proteins*/immunology , Protozoan Proteins*/genetics, Animals ; Mice ; Female ; Epitopes, B-Lymphocyte/immunology ; Epitopes, B-Lymphocyte/genetics ; Recombinant Fusion Proteins/immunology ; Recombinant Fusion Proteins/genetics ; Disease Models, Animal ; Adjuvants, Immunologic ; Immunogenicity, Vaccine ; Antigens, Surface
مستخلص: In the Americas, P. vivax is the predominant causative species of malaria, a debilitating and economically significant disease. Due to the complexity of the malaria parasite life cycle, a vaccine formulation with multiple antigens expressed in various parasite stages may represent an effective approach. Based on this, we previously designed and constructed a chimeric recombinant protein, PvRMC-1, composed by PvCyRPA, PvCelTOS, and Pvs25 epitopes. This chimeric protein was strongly recognized by naturally acquired antibodies from exposed population in the Brazilian Amazon. However, there was no investigation about the induced immune response of PvRMC-1. Therefore, in this work, we evaluated the immunogenicity of this chimeric antigen formulated in three distinct adjuvants: Stimune, AddaVax or Aluminum hydroxide (Al(OH)3) in BALB/c mice. Our results suggested that the chimeric protein PvRMC-1 were capable to generate humoral and cellular responses across all three formulations. Antibodies recognized full-length PvRMC-1 and linear B-cell epitopes from PvCyRPA, PvCelTOS, and Pvs25 individually. Moreover, mice's splenocytes were activated, producing IFN-γ in response to PvCelTOS and PvCyRPA peptide epitopes, affirming T-cell epitopes in the antigen. While aluminum hydroxide showed notable cellular response, Stimune and Addavax induced a more comprehensive immune response, encompassing both cellular and humoral components. Thus, our findings indicate that PvRMC-1 would be a promising multistage vaccine candidate that could advance to further preclinical studies.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Matos, Soares, Rodrigues-da-Silva, Rodolphi, Albrecht, Donassolo, Lopez-Camacho, Ano Bom, Neves, Conte, Pratt-Riccio, Daniel-Ribeiro, Totino and Lima-Junior.)
References: Elife. 2017 Sep 26;6:. (PMID: 28949293)
Vet Microbiol. 2002 Jan 3;84(1-2):155-68. (PMID: 11731168)
Eur J Immunol. 2009 Aug;39(8):2004-7. (PMID: 19672886)
Science. 2005 Dec 2;310(5753):1442-3. (PMID: 16322444)
Eur J Immunol. 2002 Mar;32(3):752-60. (PMID: 11870619)
Annu Rev Immunol. 1997;15:749-95. (PMID: 9143706)
PLoS One. 2010 Aug 19;5(8):e12294. (PMID: 20808868)
Int J Mol Sci. 2023 Jul 18;24(14):. (PMID: 37511330)
Vaccine. 2003 Feb 14;21(9-10):1006-22. (PMID: 12547615)
PLoS One. 2010 Jan 22;5(1):e8787. (PMID: 20107498)
Expert Rev Vaccines. 2015;14(12):1587-608. (PMID: 26468755)
Exp Parasitol. 2020 Sep;216:107944. (PMID: 32619431)
Infect Immun. 2012 Jan;80(1):461-8. (PMID: 22025519)
Clin Vaccine Immunol. 2012 Sep;19(9):1465-73. (PMID: 22815152)
Vaccine. 2008 Jan 24;26(4):552-61. (PMID: 18162266)
Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1179-84. (PMID: 25583518)
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9952-7. (PMID: 12886016)
J Immunol. 2002 Feb 1;168(3):1348-55. (PMID: 11801675)
Vet Immunol Immunopathol. 1994 Mar;40(3):225-41. (PMID: 8160361)
Malar J. 2005 Sep 29;4:48. (PMID: 16194274)
Sci Rep. 2021 Jan 13;11(1):1220. (PMID: 33441615)
Adv Immunol. 1996;62:61-130. (PMID: 8781267)
Vaccine. 2005 May 2;23(24):3131-8. (PMID: 15837212)
Vaccine. 2003 Mar 7;21(11-12):1219-23. (PMID: 12559801)
Hum Vaccin Immunother. 2013 Dec;9(12):2558-65. (PMID: 23978931)
J Control Release. 2013 May 28;168(1):10-7. (PMID: 23500060)
Lancet. 2004 Jan 10;363(9403):150-6. (PMID: 14726170)
ACS Infect Dis. 2023 Oct 13;9(10):1795-1814. (PMID: 37708228)
Mem Inst Oswaldo Cruz. 1992;87 Suppl 3:229-34. (PMID: 1343695)
Cell. 2019 Jun 27;178(1):216-228.e21. (PMID: 31204103)
PLoS One. 2018 Jun 8;13(6):e0198371. (PMID: 29883485)
NPJ Vaccines. 2023 Aug 18;8(1):124. (PMID: 37596283)
Vaccine. 2003 Jan 17;21(5-6):419-30. (PMID: 12531640)
Pathogens. 2017 Mar 22;6(1):. (PMID: 28327531)
Parasitol Int. 2022 Oct;90:102592. (PMID: 35489701)
Exp Parasitol. 2012 Apr;130(4):384-93. (PMID: 22343045)
BMC Biol. 2010 Apr 12;8:37. (PMID: 20385031)
Cells. 2021 Jun 15;10(6):. (PMID: 34203839)
Nature. 1976 Sep 2;263(5572):57-60. (PMID: 986561)
Sci Rep. 2016 Sep 14;6:32575. (PMID: 27624667)
PLoS One. 2008 Jul 09;3(7):e2636. (PMID: 18612426)
J Virol. 2013 Nov;87(22):12187-95. (PMID: 24006434)
J Control Release. 2022 Sep;349:699-711. (PMID: 35907590)
J Infect Dis. 2013 Aug 1;208(3):479-88. (PMID: 23624363)
Science. 2005 Dec 2;310(5753):1510-2. (PMID: 16322460)
J Immunol. 2012 Jun 15;188(12):6225-37. (PMID: 22593616)
J Biol Chem. 2005 Apr 8;280(14):13406-14. (PMID: 15684430)
J Immunol Methods. 1989 Jul 26;121(2):157-66. (PMID: 2474611)
Mol Microbiol. 2006 Mar;59(5):1369-79. (PMID: 16468982)
Vaccine. 2004 Sep 9;22(27-28):3727-37. (PMID: 15315853)
Med Microbiol Immunol. 2019 Dec;208(6):731-745. (PMID: 31025102)
Vaccine. 2015 Apr 8;33(15):1873-9. (PMID: 25698487)
Parasitol Int. 2021 Oct;84:102411. (PMID: 34166786)
Front Immunol. 2017 Feb 07;8:77. (PMID: 28223984)
Parasitology. 2016 Feb;143(2):187-98. (PMID: 26743529)
Vaccine. 2008 Aug 12;26(34):4338-44. (PMID: 18573299)
Vaccine. 2003 Apr 2;21(15):1650-7. (PMID: 12639486)
Vaccine. 2006 Mar 15;24(12):2007-16. (PMID: 16377036)
Vet Immunol Immunopathol. 1998 Feb 27;61(2-4):291-304. (PMID: 9613442)
Nat Microbiol. 2018 Nov;3(11):1224-1233. (PMID: 30349082)
Front Immunol. 2022 Sep 22;13:1005332. (PMID: 36211427)
Biomed Res Int. 2022 Jul 6;2022:7205241. (PMID: 35845955)
Appl Microbiol Biotechnol. 2012 Apr;94(1):151-61. (PMID: 22170105)
Genes (Basel). 2021 Oct 21;12(11):. (PMID: 34828264)
Vaccine. 2013 Jan 2;31(2):373-9. (PMID: 23146673)
FEMS Microbiol Lett. 2002 Feb 5;207(2):111-20. (PMID: 11958927)
Hum Vaccin Immunother. 2015;11(2):477-88. (PMID: 25692535)
PLoS Negl Trop Dis. 2017 Feb 3;11(2):e0005344. (PMID: 28158176)
PLoS One. 2010 Apr 16;5(4):e9862. (PMID: 20419125)
Front Immunol. 2021 Aug 27;12:729086. (PMID: 34512663)
Infect Genet Evol. 2019 Sep;73:287-294. (PMID: 31077839)
PLoS One. 2013 Aug 16;8(8):e71610. (PMID: 23977087)
Vaccine. 2005 Feb 10;23(12):1502-6. (PMID: 15670886)
فهرسة مساهمة: Keywords: BALB/c; immunization; immunogenicity; in silico simulation; multistage chimeric protein; plasmodium vivax; vaccine
المشرفين على المادة: 0 (Antigens, Protozoan)
0 (Antibodies, Protozoan)
0 (Malaria Vaccines)
0 (Protozoan Proteins)
0 (Epitopes, B-Lymphocyte)
0 (Recombinant Fusion Proteins)
0 (Pvs25 protein, P vivax)
0 (Adjuvants, Immunologic)
0 (Antigens, Surface)
تواريخ الأحداث: Date Created: 20240704 Date Completed: 20240704 Latest Revision: 20240726
رمز التحديث: 20240726
مُعرف محوري في PubMed: PMC11219565
DOI: 10.3389/fimmu.2024.1392043
PMID: 38962015
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2024.1392043